Cellfina Results Last Five Years, New Ultherapy Guidelines

Thursday, October 11, 2018 | Personnel/Company News , Lasers & Light Devices , Product Launches and Updates , Research and Publications , American Society for Dermatologic Surgery , Merz


One Cellfina treatment improves the appearance of cellulite on the thighs and buttocks for five years, according to new data presented by Merz at the Annual Meeting of the American Society for Dermatologic Surgery (ASDS) in Phoenix, AZ.

This new data builds upon Cellfina’s duration of effectiveness, which was previously three years - the longest FDA clearance for a cellulite treatment.

Of the patients who completed the five-year follow up, evaluators rated 100 percent of the patients as having noticeable improvement after five years.

“With this new five-year data, patients and physicians should feel confident that Cellfina® is the right step toward proven, noticeable and lasting results in the improved appearance of cellulite,” says Chestnut Hill, MA-based dermatologist and Cellfina five-year study group member Michael Kaminer, MD, in a news release “Creams and other cellulite treatments lead to limited patient satisfaction, while Cellfina patients experience enduring results. The study results confirm what we regularly see in practice.”

New Ultherapy Guidelines

Merz also presented new guidelines for improving Ultherapy® Treatment results and patient satisfaction developed by a panel of expert aesthetic physicians called the Ultherapy Treatment Consensus Group (Group).

The Group concluded that the use of ultrasound visualization is the single-most important factor for selecting optimal treatment depth to achieve ideal outcomes and increase patient satisfaction.

“The expert physician panel agreed that Ultherapy is a key foundational aesthetic treatment and the gold standard for nonsurgical lifting of the skin,” says Sabrina Guillen Fabi, MD, a cosmetic dermatologist in San Diego, Calif. and lead author of the Ultherapy® consensus guidelines. “The guidelines extend the clinical data and valuable evidence available for physicians to be confident that treating patients with Ultherapy® leads to proven outcomes.”

 In addition to the two oral presentations, Merz will be presenting updates on aesthetics products including:

  • Diluted and Hyperdiluted Calcium Hydroxylapatite (Radiesse) for Skin Tightening: Guidelines from a Global Consensus Panel
  • Comparison of Xeomin to botulinum neurotoxin type A formulations in Asia
  • Escalating Doses of IncobotulinumtoxinA (Xeomin) for Extended Treatment of Glabellar Frown Lines: Results from a Randomized, Double-Blind Study
  • The Describe PFD Patch in Picosecond and Q-Switched Laser-Assisted Tattoo Removal: Safety in Fitzpatrick IV-VI Skin Types

 

Next Story

Comments

You must be logged in to leave a comment.